↓ Skip to main content

Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol

Overview of attention for article published in BMC Cancer, March 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol
Published in
BMC Cancer, March 2017
DOI 10.1186/s12885-017-3144-5
Pubmed ID
Authors

R. K. Charaghvandi, B. van Asselen, M. E. P. Philippens, H. M. Verkooijen, C. H. van Gils, P. J. van Diest, R. M. Pijnappel, M. G. G. Hobbelink, A. J. Witkamp, T. van Dalen, E. van der Wall, T. C. van Heijst, R. Koelemij, M. van Vulpen, H. J. G. D. van den Bongard

Abstract

A shift towards less burdening and more patient friendly treatments for breast cancer is currently ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy. The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose, ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving surgery is scheduled at six months following RT. Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic outcome will be evaluated by the treating radiation oncologist, patient and 'Breast Cancer Conservation Treatment cosmetic results' software. Recurrence and survival rates will be assessed. The patients will be followed up to 10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping. The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment. ClinicalTrials.gov registration number NCT02316561 . The trial was registrated prospectively on October 10th 2014.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 101 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 15%
Student > Master 13 13%
Student > Ph. D. Student 11 11%
Other 8 8%
Student > Bachelor 8 8%
Other 18 18%
Unknown 28 28%
Readers by discipline Count As %
Medicine and Dentistry 31 31%
Nursing and Health Professions 11 11%
Biochemistry, Genetics and Molecular Biology 5 5%
Business, Management and Accounting 2 2%
Immunology and Microbiology 2 2%
Other 12 12%
Unknown 38 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2017.
All research outputs
#18,578,649
of 23,011,300 outputs
Outputs from BMC Cancer
#5,461
of 8,359 outputs
Outputs of similar age
#235,062
of 307,953 outputs
Outputs of similar age from BMC Cancer
#82
of 130 outputs
Altmetric has tracked 23,011,300 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,359 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,953 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.